Prazer Therapeutics Inc. has identified mitogen-activated protein kinase 14 (MAPK14) inhibitors reported to be useful for the treatment of inflammatory disorders.

Glenmark Pharmaceuticals Ltd. has divulged...

F. Hoffmann-La Roche Ltd. has synthesized...

Alphamab (Jiangsu) Biopharmaceuticals Co. Ltd. has identified new antibody-drug conjugate (ADC) comprising bispecific antibodies targeting HER2 covalently bound to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.

Hinova Pharmaceuticals Inc. has presented proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to tyrosine-protein phosphatase nonreceptor type 11 (PTPN11)-targeting moiety through a linker reported to be useful for the treatment of cancer, Noonan and LEOPARD syndromes.

Hangzhou Innogate Pharma Co. Ltd. has discovered histone acetyltransferase KAT6A inhibitors reported to be useful for the treatment of cancer.

Shengke Pharmaceuticals (Jiangsu) Ltd. has described proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of atherosclerosis, myocardial infarction, nonalcoholic steatohepatitis, stroke, type 2 diabetes, dyslipidemia, hyperphosphatemia and diabetic nephropathy.

Betta Pharmaceuticals Co. Ltd. has divulged aryl or heteroaryl amides acting as MALT1 inhibitors.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.